Related Experiment Video

Updated: May 19, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Current Landscape of Anti-HER2 Targeted Therapy in Breast Cancer: Challenges and Future Perspectives

Pooja Bharali1, Vikrant Mehta2, Subhash Chand1

  • 1National Institute of Biologicals, Ministry of Health & Family Welfare, Noida, Uttar Pradesh, India.

Cancer Investigation
|May 18, 2026
PubMed

Insights

New strategies are emerging to combat HER2-positive breast cancer, addressing treatment resistance and high costs. This review explores advanced therapies and biosimilars to improve patient outcomes in metastatic disease.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • HER2-positive breast cancer is an aggressive subtype.
  • Current treatments include monoclonal antibodies (trastuzumab, pertuzumab), ADCs, TKIs, and chemotherapy.
  • Despite efficacy, challenges like resistance, toxicity, and cost remain.

Purpose of the Study:

  • To review emerging therapeutic strategies for HER2-positive breast cancer.
  • To address challenges of resistance, toxicity, and cost.
  • To enhance treatment accessibility and patient outcomes.

Main Methods:

  • Literature review of current and emerging therapies.
  • Analysis of strategies to overcome resistance mechanisms.
  • Evaluation of cost-effective treatment options.

Main Results:

  • Advanced monoclonal antibodies show promise.
  • Combination regimens offer potential benefits.
  • Downstream pathway inhibitors and biosimilars are key emerging strategies.

Conclusions:

  • Overcoming therapeutic resistance is crucial for improving outcomes.
  • Enhancing treatment accessibility through cost-effective options like biosimilars is essential.
  • Future research should focus on novel combinations and resistance-targeting agents for HER2-positive metastatic breast cancer.
Keywords:
HER2-positive metastatic breast cancerantibody drug conjugatesbiosimilarsmonoclonal antibodiestyrosine kinase inhibitors

More Related Videos

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...